All In Biotech

Drug Trial Radar · NCT01076764

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

Randomized, Double-blind, Triple-dummy Trial to Compare the Efficacy of Otamixaban With Unfractionated Heparin + Eptifibatide, in Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy

Last checked: Nov 19, 2026Latest source record: May 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 13,220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

13,220

Actual

Start

Apr 2010

Primary completion

May 2013

Study completion May 2013

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: * To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide Secondary Objectives: * To demonstrate the superior efficacy (composite of all-cause death + MI + any stroke) of Otamixaban as compared to UFH + Eptifibatide * To document the effect of Otamixaban on rehospitalization or prolongation of hospitalization due to a new episode of myocardial ischemia/myocardial infarction as compared to UFH + eptifibatide * To document the effect on mortality (all cause death) of Otamixaban as compared to UFH + eptifibatide * To document the safety of Otamixaban as compared to UFH + eptifibatide * To document the effect of Otamixaban on thrombotic procedural complications during the index Percutaneous Coronary Intervention (PCI) as compared to UFH + eptifibatide

Conditions

  • Acute Coronary Syndrome

Interventions

  • OtamixabanDrug

    Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion

  • Placebo (for Otamixaban)Drug

    Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion

  • UFHDrug

    Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion

  • Placebo (for UFH)Drug

    Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion

  • EptifibatideDrug

    Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion

  • Placebo (for Eptifibatide)Drug

    Pharmaceutical form: Intravenous (IV) solution Route of administration: IV bolus followed by continuous IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Adjudicated double composite of all-cause of death and new myocardial infarctionTime frame: from randomization (day 1) to day 7
  2. Safety: Adjudicated Thrombolysis In Myocardial Infarction (TIMI) significant bleeding (composite of TIMI major and minor)Time frame: from day 1 to day 7

Locations

607 sites in 55 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840015

    Huntsville, Alabama

  • Investigational Site Number 840569

    Phoenix, Arizona

  • Investigational Site Number 840703

    Phoenix, Arizona

  • Investigational Site Number 840101

    Anaheim, California

  • Investigational Site Number 840151

    Anaheim, California

  • Investigational Site Number 840213

    Beverly Hills, California

  • Investigational Site Number 840572

    Huntington Beach, California

  • Investigational Site Number 840201

    Long Beach, California

  • Investigational Site Number 840071

    Los Angeles, California

  • Investigational Site Number 840557

    Los Angeles, California

  • Investigational Site Number 840903

    Northridge, California

  • Investigational Site Number 840065

    San Francisco, California

  • Investigational Site Number 840561

    Santa Rosa, California

  • Investigational Site Number 840721

    Littleton, Colorado

  • Investigational Site Number 840551

    Bridgeport, Connecticut

  • Investigational Site Number 840166

    New Haven, Connecticut

  • Investigational Site Number 840520

    Washington D.C., District of Columbia

  • Investigational Site Number 840185

    Fort Lauderdale, Florida

  • Investigational Site Number 840028

    Jacksonville, Florida

  • Investigational Site Number 840047

    Lake Mary, Florida

  • Investigational Site Number 840500

    Melbourne, Florida

  • Investigational Site Number 840706

    Miami, Florida

  • Investigational Site Number 840009

    Ocala, Florida

  • Investigational Site Number 840146

    Ocala, Florida

  • Investigational Site Number 840577

    Orlando, Florida

  • Investigational Site Number 840021

    Sarasota, Florida

  • Investigational Site Number 840902

    St. Petersburg, Florida

  • Investigational Site Number 840508

    Tampa, Florida

  • Investigational Site Number 840719

    Gainesville, Georgia

  • Investigational Site Number 840532

    Boise, Idaho

  • Investigational Site Number 840105

    Aurora, Illinois

  • Investigational Site Number 840190

    Chicago, Illinois

  • Investigational Site Number 840205

    Chicago, Illinois

  • Investigational Site Number 840521

    Harvey, Illinois

  • Investigational Site Number 840148

    Joliet, Illinois

  • Investigational Site Number 840042

    Hammond, Indiana

  • Investigational Site Number 840554

    Indianapolis, Indiana

  • Investigational Site Number 840560

    Muncie, Indiana

  • Investigational Site Number 840904

    Ames, Iowa

  • Investigational Site Number 840058

    West Des Moines, Iowa

Showing 40 of 607 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.